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Abstract
Background: The low fermentable oligosaccharide, disaccharide, 
monosaccharide and polyol (FODMAP) diet causes significant clini-
cal improvement in patients with irritable bowel syndrome (IBS). 
Joint hypermobility syndrome (JHS), defined as musculoskeletal 
symptoms in a hypermobile individual in the absence of systemic 
rheumatological disease, may be associated with functional gastroin-
testinal symptoms, including IBS. The aim of this study is to examine 
whether JHS can affect the response to the low FODMAP diet in pa-
tients with IBS.
Methods: In this retrospective study, we included patients with IBS 
according to Rome III criteria who had followed a low FODMAP 
diet. Symptoms scores were measured before and after the low FOD-
MAP diet.
Results: A total of 165 patients (130 females, age 44 ± 14 years) were 
included. Diarrhea predominant IBS (IBS-D) was present in 40.6% of 
our patients while JHS was present in 21.2%. The score for abdominal 
pain was higher for JHS compared to non-JHS prior to intervention 
(P = 0.011). Symptoms improved in both groups of patients after a 
low FODMAP diet (P < 0.0001). The largest effects were shown with 
significant decreases of the average score and bloating. When broken 
down by JHS and IBS type, a low FODMAP diet significantly im-
proved pain, bloating, diarrhea, constipation, and the average score 
with the largest effect in JHS/constipation predominant IBS (IBS-C), 
JHS/mixed IBS and unclassified IBS (IBS-M), JHS/IBS-D, non-JHS/
IBS-C and JHS/IBS-M, respectively.
Conclusions: Our study suggests that a low FODMAP diet has a 
greater effect on IBS symptoms in JHS than non-JHS patients.
Keywords: Joint hypermobility syndrome; Irritable bowel syndrome; 
FODMAP; Pain; Bloating
Introduction
Irritable bowel syndrome (IBS) is a chronic functional bowel 
disease with high prevalence in the general population [1]. The 
prevalence of IBS ranges between 7% and 21% depending on 
the country and criteria used, and it has an adverse effect on the 
patient’s quality of life [2]. Four IBS subtypes are suggested by 
the Rome IV criteria based on stool form: diarrhea predomi-
nant IBS (IBS-D), constipation predominant IBS (IBS-C), 
mixed IBS and unclassified IBS (IBS-M) [3]. IBS-D is consid-
ered the most common subtype with a prevalence of 40-60% 
of all IBS [4, 5]. Treatment of IBS depends on the predominant 
symptom that the individual is experiencing [6].
There is increased recognition that dietary factors have a 
significant role to play in the development of IBS symptoms 
[7]. Fermentable oligosaccharides, disaccharides, monosac-
charides and polyols (FODMAPs) are fermented rapidly by 
gut microflora, slowly absorbed and osmotically active. In-
creased osmotic load and luminal changes secondary to gas 
induced distension will cause IBS symptoms in some patients 
[8, 9]. Patients with IBS have heightened gut sensitivity and/or 
altered motility and might experience symptoms such as diar-
rhea, excessive flatulence, bloating and/or abdominal cramps 
when exposed to foods rich in FODMAPs. The associated 
visceral hypersensitivity explains symptom development in 
response to FODMAP-containing foods [10]. Recent evidence 
supports the implementation of the low FODMAP diet for the 
treatment of IBS patients and it is indeed now considered as 
a first-line dietetic intervention [11, 12]. Many studies have 
demonstrated that the low FODMAP diet achieves a signifi-
cant improvement in symptoms such as bloating, abdominal 
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pain and flatulence in IBS patients compare to a standard diet 
[13-15].
Functional gastrointestinal disorders are reported to be 
more common in patients with a non-inflammatory connective 
tissue disorder known as benign joint hypermobility syndrome 
(JHS) [16, 17]. JHS is defined as musculoskeletal symptoms 
in a hypermobile individual in the absence of systemic rheu-
matological disease, and its prevalence is around 3% of the 
population [18, 19]. An essential feature of JHS is generalized 
joint hypermobility, which refers to the characteristic of being 
able to actively and/or passively move joints beyond normal 
limits [20]. Generalized joint hypermobility can be identified 
in some well-defined inherited connective tissue disorders, in-
cluding Ehlers-Danlos syndrome [21], Marfan syndrome and 
osteogenesis imperfecta [17]. Joint hypermobility can affect a 
few joints (localized or monoarticular joint hypermobility) or 
several joints in multiple body sites. Generalized joint hyper-
mobility, in the absence of other symptoms, is considered to 
be a harmless trait [22, 23]. The definitive diagnosis of JHS 
requires fulfilling the Brighton criteria, but generalized joint 
hypermobility can be screened for using a simple validated 
5-point questionnaire or using the Beighton score (Supplemen-
tary Table 1) (www.gastrores.org).
The systemic complications of JHS include altered pain 
processing, autonomic dysfunction and chronic fatigue [24]. 
Patients with co-existent JHS and gastrointestinal symptoms 
experience mostly abdominal pain, bloating and nausea, fol-
lowed by reflux symptoms, vomiting, constipation and diar-
rhea [25]. Fikree et al [26] reported that JHS patients referred 
from rheumatology clinics with gastrointestinal symptoms 
were significantly younger than the non-JHS patients and pre-
dominately female (95.5%). JHS patients complain of multi-
ple gastrointestinal symptoms although mechanisms for this 
remain unknown. Chronic exposure to pain and visceral hy-
persensitivity with altered pain processing might be involved.
Clinical management of functional gastrointestinal symp-
toms in patients with JHS can be challenging, particularly in 
patients with associated extra-intestinal chronic functional 
symptoms and pain. Food restriction and dysfunctional psy-
chology can therefore lead to poor nutritional status and 
weight loss that can worsen the symptoms of JHS resulting in 
worsening fatigue and pain. Nutritional and lifestyle interven-
tions (e.g. regular fiber intake or restrictions of foods contrib-
uting to symptoms) are a recommended therapeutic approach 
in JHS with functional gastrointestinal symptoms [18]. Hence, 
the purpose of the current study is to examine the efficacy of a 




This study was based at University College London Hospitals 
(UCLH) NHS Foundation Trust, a national referral center of 
congenital connective tissue disorders and a tertiary neurogas-
troenterology referral center. Participants were consecutively 
recruited from patients who visited the Gastroenterology De-
partment at UCLH between January 2012 and June 2015. In-
dividual patient data was anonymized, and regulatory approv-
al was granted by the site institutional review board (2015). 
This study involved the retrospective review of existing data 
and records, and was considered a service evaluation study. 
Hence written, informed consent was waived and ethical ap-
proval was not required, according to the decision of institu-
tional review board. The study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki as reflected in 
a priori approval by the institutional review board. STROBE 
guidelines for observational studies were followed in the pre-
sent study [27].
Inclusion and exclusion criteria
Included patients were 18 years old or over, had a diagnosis of 
IBS according to Rome III criteria confirmed by a gastroenter-
ologist, were medically safe for a low FODMAP intervention 
and willing to comply with the dietary protocol. Exclusion 
criteria were loss to follow-up, pregnancy, patients who had 
undergone previous upper gastrointestinal surgery that may 
affect dietary intake and any other medical condition that pre-
vented patients following a food restricted diet. Data were 
collected retrospectively through UCLH electronic patients’ 
records and the IBS databases held by the neurogastroenterol-
ogy team.
Data collection
The following data were collected.
Demographics and IBS diagnosis
Age, gender, and IBS subtype, based on Rome III criteria (di-
arrhea, constipation or mixed).
Hypermobility
Patients with a positive diagnosis made by an experienced 
rheumatology consultant were classified as JHS based on the 
Brighton criteria [24] (Supplementary Table 1) (www.gas-
trores.org). The remaining patients were classified as non-JHS.
Lactose or fructose intolerance
Breath tests were carried out to diagnose lactose and fructose 
malabsorption. In both tests, an increase of H2 concentration 
≥ 20 ppm in two consecutive readings above the basal value 
following ingestion of the test meal was considered lactose in-
tolerance or fructose intolerance [28]. Positive breath tests as-
sist dieticians during the reintroduction phase of the low FOD-
MAP diet intervention, since lactose or fructose intolerance 
Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org 29












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org30
Joint Hypermobility and the Low FODMAP Diet  Gastroenterol Res. 2019;12(1):27-36
largely precludes their reintroduction into patients’ diets [13].
Symptoms score
Symptom scores for pain, bloating, diarrhea and constipation 
were measured before and after the dietetic intervention with a 
visual analogue scale ranging from 0 to 5. Patients were asked 
the question: How severe has your “symptom” been over the 
last 10 days?
Diet
Patients fulfilling the Rome III criteria for IBS were invited to 
adhere to the low FODMAP diet. This is recommended by the 
UK National Institute for Health and Care Excellence (NICE) 
in the management of patients with IBS [29]. Patients were 
referred to group or individual guidance on the low FODMAP 
diet, both led by a trained dietician. Group guidance was car-
ried out with over 10 patients as a group while individual guid-
ance involved a clinic consultation. The process of carrying 
out the low FODMAP diet involves an informative session 
with education on restriction of dietary types, helping patients 
plan menus and encourage patients to develop a strategy plan 
for the diet ahead.
Statistical Analysis
Data are presented as mean and standard deviation (SD) or me-
dian and interquartile range (IQR) for continuous data and ab-
solute and relative frequency for categorical data, respectively. 
Univariate analyses were conducted with Chi-square test and 
Mann-Whitney test for non-normally distributed data. Regres-
sion was performed with a mixed effects repeated measures 
model. For the sake of brevity, we present the coefficients, the 
significance and the F tests from of the linear mixed model 
(type III Wald F tests with Kenward-Roger degrees of free-
dom approximation). The aim of the model was to investigate 
temporal trend of symptoms post intervention. Post estimation 
contrasts were estimated and the effect was presented as the 
standardized mean difference (SMD) to allow comparabil-
ity. The strength of association was categorized as following: 
small, SMD = 0.2; medium, SMD = 0.5; and large, SMD = 
0.8 [30]. A P-value ≤ 0.05 was considered significant. For data 
analysis, IBM SPSS Statistics (Release 22.0.0. 2010, Chicago 
(IL), USA: SPSS, Inc., an IBM Company) and STATA 14.0 
(Stata Corp, College Station, Texas) were used.
Results
Demographics, JHS and IBS characteristics
Our sample included 165 patients (130 females) with mean 
age 44 ± 14 years. IBS-D subtype was the most common in 
our sample (40.6%) followed by IBS-M (38.2%) and IBS-C 
(21.2%). Approximately 22% patients were positive for lactose 
intolerance and 16% were positive for fructose intolerance. 
Thirty-five patients had a positive diagnosis for JHS (21.2%). 
Sixty percent of patients received group vs. individual low 
FODMAP training. The median duration of trialing the low 
FODMAP was approximately 2 months (63 (56 - 83) days).
Patients with JHS were predominantly female (P = 0.003) 
and median age was lower than non-JHS patients (JHS: 37 
years (27 - 47) vs. non-JHS: 42 years (34 - 56)), Mann-Whitney 
P = 0.001). The score for pain was higher for JHS compared to 
non-JHS prior to intervention (JHS: median 3.8 (3.3 - 5.0) vs. 
3.5 (2.5 - 3.8), P = 0.011). No differences were found for bloat-
ing, diarrhea, constipation and average scores between both 
groups at baseline. Also, no differences were found for positive 
lactose or fructose tests, duration of the low FODMAP diet and 
whether individual or group training was given. The distribu-
tion of symptoms scores according to IBS subtype is shown in 
Table 1. The highest scores were observed of pain and bloating.
Repeated measures regressions
The symptoms were analyzed using linear mixed-effects re-
gression, with the xtmixed package in Stata. In contrast to a 
more traditional approach with data aggregation and repeat-
ed-measures analysis of variance analysis, xtmixed allows 
controlling for the variance associated with random factors 
without data aggregation [31]. By using random effects for 
subjects, we controlled for the influence of different mean 
symptoms associated with the variables JHS and IBS type and 
their interaction over time. The models are:
painij = β0 + β1jhs*timeij + β2ibstype*timeij 
+ β3jhs*ibstype*timeij + uj + εij
bloatingij = β0 + β1jhs*timeij + β2ibstype*timeij 
+ β3jhs*ibstype*timeij + uj + εij
diarrheaij = β0 + β1jhs*timeij + β2ibstype*timeij 
+ β3jhs*ibstype*timeij + uj + εij
constipationij = β0 + β1jhs*timeij + β2ibstype*timeij 
+ β3jhs*ibstype*timeij + uj + εij
averscoreij = β0 + β1jhs*timeij + β2ibstype*timeij 
+ β3jhs*ibstype*timeij + uj + εij
where i = 1 (pre low FODMAP diet), 2 (post low FODMAP 
diet), j = 1, 2, …, 165 patients, uj is the individual subject ef-
fect serving to shift the regression line up or down according to 
each patient and εij are the errors of the regression. The reason 
to choose interaction terms is that JHS and IBS type are sig-
nificantly associated. The models of each symptom were sig-
nificant (P < 0.0001). Overall the results of the mixed models 
are as following.
Pre-post low FODMAP diet
Symptoms improved in all patients after a low FODMAP diet 
(P < 0.0001) (Tables 2, 3). The largest effect was shown in the 
significant decrease of average score (SMD = -2.05 (95% CI: 
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-2.42, -1.67)) followed by a significant decrease in bloating 
(SMD = -1.50, (95% CI: -1.85, -1.16)).
Impact on IBS symptoms with regard to the presence of JHS
Symptoms improved post low FODMAP diet in both JHS and 
non-JHS patients (P < 0.001) (Table 3). However, effects were 
more prominent in the JHS group with larger SMDs for each 
symptom in the JHS group compared to the non-JHS group 
(Figs. 1, 2). For example, pain improved with a larger effect 
in JHS patients compared to non-JHS patients (SMD -1.89 vs. 
-1.38, respectively) (Table 3).
Impact on IBS symptoms with reference to IBS type
Symptoms improved significantly with post low FODMAP 
diet in all IBS subgroups (Tables 2, 3). The low FODMAP diet 
significantly improved pain, bloating, diarrhea and the aver-
age score with the largest effect in the IBS-D group (SMDs 
= -2.01, (95% CI: -2.84, -1.19), -1.98 (95% CI: -2.80, -1.17), 
-2.51 (95% CI: -3.41, -1.61), and -2.70 (95% CI: -3.63, -1.77), 
respectively), while constipation improved with the largest ef-
fect in the IBS-C group (SMD = -1.35, (95% CI: -1.88, -0.81)).
Impact on IBS symptoms when considering interaction of JHS 
and IBS type
When broken down by JHS and IBS type, most symptoms im-
proved significantly post low FODMAP diet (Table 3). A low 
FODMAP diet significantly improved pain with the largest ef-
fect in the JHS/IBS-C group (SMD = -2.62, (95% CI: -4.31, 
-0.93)); significantly improved bloating with the largest effect 
in the JHS/IBS-M group (SMD = -2.41, (95% CI: -4.36, -0.47)); 
significantly improved diarrhea with the largest effect in the 
JHS/IBS-D group (SMD = -4.00, (95% CI: -6.66, -1.35)); signif-
icantly improved constipation with the largest effect in the non-
JHS/IBS-C group (SMD = -2.23, (95% CI: -3.27, -1.19)); and 
significantly improved the average score with the largest effect 
in the JHS/IBS-M group (SMD = -4.33, (95% CI: -7.15, -1.52)). 
Overall, JHS seems to affect response to symptoms mainly with 
regards to pain, bloating, diarrhea and the average score.
Although there was no gender difference in response for 
JHS individuals with IBS, female patients with JHS exhibited 
larger effects for all symptoms compared to non-JHS patients 
(Supplementary Tables 2, 3) (www.gastrores.org).
Discussion
To our knowledge, this is the first study to investigate response 
to the low FODMAP diet in patients with IBS and co-existent 
congenital connective tissue disorder, JHS which has been as-
sociated with frequent and more severe functional gut disorders. 
Our findings show that JHS patients have significant improve-
ment in their pain, bloating, diarrhea and constipation after the 
low FODMAP diet. The overall symptom score improvement 
for both JHS and non-JHS patients were statistically significant 
which stated that the low FODMAP diet is effective in both JHS 
and non-JHS group. However, IBS symptoms demonstrated a 
Table 2.  Mixed Model Results for Each Symptom
Pain Bloating Diarrhea Constipation Average score
beta P beta P beta P beta P beta P
JHS # time
  No # post low FODMAP diet -0.94 < 0.0001 -1.23 < 0.0001 -0.84 < 0.0001 0.81 < 0.0001 -0.55 < 0.0001
  Yes # pre low FODMAP diet 0.70 0.028 0.48 0.128 -0.48 0.151 -0.17 0.597 0.14 0.467
  Yes # post low FODMAP diet -0.77 0.064 -1.07 0.009 -1.3 0.003 0.60 0.154 -0.63 0.009
IBS type # time
  IBS-D # post low FODMAP diet 0.22 0.225 0.41 0.057 -0.37 0.102 -0.65 0.003 -0.10 0.449
  IBS-C # pre low FODMAP diet 0.06 0.064 0.27 0.327 -2.03 < 0.0001 1.96 < 0.0001 0.06 0.686
  IBS-C # post low FODMAP diet 0.05 0.049 0.33 0.221 -0.99 < 0.0001 -0.02 0.943 -0.16 0.319
  IBS-M # pre low FODMAP diet -0.07 -0.073 -0.04 0.835 0.18 0.416 0.98 < 0.0001 0.26 0.037
  IBS-M # post low FODMAP diet 0 omitted 0 omitted 0 omitted 0 omitted 0 omitted
JHS #IBS Type # time
  Yes # IBS-C # pre low FODMAP diet 0.06 0.912 -0.17 0.735 0.46 0.388 0.83 0.109 0.29 0.326
  Yes # IBS-C # post low FODMAP diet 0.74 0.153 0.29 0.571 0.34 0.529 1.10 0.033 0.30 0.030
  Yes # IBS-M # pre low FODMAP diet -0.97 0.067 -0.75 0.152 0.91 0.097 1.58 0.003 0.19 0.535
  Yes # IBS-M # post low FODMAP diet -0.92 0.085 -0.65 0.213 -0.34 0.540 1.07 0.044 -0.21 0.498
Constant 3.31 < 0.0001 3.63 < 0.0001 1.81 < 0.0001 0.20 0.200 2.32 < 0.0001
F test < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
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bigger improvement in JHS patients. Researchers have found 
bloating, abdominal pain and diarrhea are the symptoms that 
improve significantly on a low FODMAP diet, whereas consti-
pation was often reported to non-significantly improve or not 
improve [32, 33]. A low FODMAP diet likely reduces osmotic 
fluid transit into the gut lumen and consequently increases the 
chances of having constipation. Interestingly, our study demon-
strated significant treatment efficacy of a low FODMAP diet in 
the constipation symptom irrespective of JHS status in IBS-C 
and a non-significant decrease in IBS-M.
Pain mechanisms in JHS patients remain poorly under-
stood. In the present study, baseline pain scores were sig-
nificantly higher in patients with JHS compared to non-JHS 
patients (median 3.8 vs. 3.5, respectively) with JHS patients 
responding with a larger effect compared to non-JHS patients 
(SMD -1.89 vs. -1.39, respectively). Pathophysiological mod-
els of JHS suggest nociceptive and neuropathic components, 
as well as pain sensitization. Pain in IBS is precipitated by 
negative emotions and expectations playing an important role 
in pain evaluation. Pain processing in IBS is mediated by func-
tional and structural brain changes with peripheral neuroendo-
crine and immune pathways are also relevant in IBS, which is 
similar to pain mechanisms in JHS [34]. Prevalence of psycho-
logical comorbidity, particularly anxiety, has been described in 
JHS and might be a contributing factor to increase body aware-
ness and pain related unhelpful behaviors [35]. The present 
study suggests that overall pain could be a result of additive 
processes in the co-existence of IBS and JHS and hence the 
low FODMAP may reduce the burden of pain in these patients.
Our sample included approximately 20% of JHS patients. 
The majority of them were female and in the second and third 
decade of age. JHS patients frequently report abdominal pain 
and severe constipation [36], and this was replicated in the pre-
sent study. It is possible that increased prevalence of chronic 
pain syndromes might be related to hormonal status and in-
creased joint laxity in younger ages, increased prevalence of 
anxiety and depression in the female population, and altered 
pain processing with heighted body awareness [37]. Constipa-
tion has been found to be particularly prevalent in both the 
pediatric and adult population with co-existent JHS disorder 
[38]. Although the mechanism is unknown, it is possible that 
abnormal connective tissue predisposes to altered colonic tran-
sit or it could be that the frequent described autonomic dys-
function contributes to colonic dysfunction. Hence, greater ef-
fectiveness of the low FODMAP diet in this group of patients 
might be secondary to a greater degree of abdominal discom-
fort relieved in patients with visceral hypersensitivity.
Some studies suggest that the low FODMAP diet is likely 
to reduce diarrhea but might not improve constipation in pa-
tients with IBS [39]. A recent audit surveyed 17 patients and 
found that 82% reported positive relief of gastrointestinal 
symptoms [40]. Shepherd et al evaluated in a randomized con-
trolled trial the clinical response in 25 patients with IBS with 
fructose malabsorption demonstrated on a hydrogen breath test 
[41]. The study proved that low FODMAPs diet could reduce 
symptoms in IBS patients, particularly in patients with fructose 
malabsorption. In a recent control and crossover study, patients 
were exposed to a low FODMAPs diet for 21 days or the typi-
cal Australian diet with at least one food high in FODMAP [11]. 
Gastrointestinal symptoms were significantly different between 
the two diets and the greatest symptom control was achieved 
and maintained after 7 days of the low FODMAP diet.
The low FODMAP diet in this study was adhered to by 
patients for over 8 weeks on average, which is in line with 
the suggested 6 - 8 weeks [10, 13]. Most patients received 
group training compared to the preferred individual training. 
Although the distribution of training type was equal among 
JHS and non-JHS patients, IBS-M patients were more likely to 
receive individual training than group training and vice versa 
for IBS-C and IBS-D. A limitation exists with respect to the 
gender distribution in the JHS group, which was skewed to-
wards a female population predominantly. When the effect of 
JHS is broken down by gender, then all symptoms were not af-
fected by a low FODMAP for male patients with JHS. Female 
patients with JHS exhibited larger effects for all symptoms 
compared to non-JHS patients (Supplementary Tables 2, 3) 
(www.gastrores.org). Another main limitation involves selec-
tion bias, since the included JHS patients were those seeking 
specialist care in tertiary rheumatology clinics; it is unclear if 
this population represents patients with JHS in the community. 
However, it is important to recognize that all IBS patients were 
referred from a neurogastroenterology clinic and likely repre-
sent a cohort of patients with more severe symptoms than the 
general population. Methodological limitations included the 
retrospective design of the study, the use of a non-validated 
symptom measurement tool and the fact that statistical analy-
ses included regression to the mean which can bias any inves-
tigation where the response to treatment is classified relative 
Figure 1. Effect sizes (SMD), according to JHS and IBS and combination.
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to initial values for a given variable without the use of an ap-
propriate control group [42].
Conclusions
In conclusion, with the increasing recognition of JHS, more 
patients from this cohort will be referred to the gastroenterol-
ogy clinic. Our study suggests that a low FODMAP diet has 
greater improvement in JHS patients than non-JHS patients 
concerning IBS symptoms (pain, diarrhea, bloating and con-
stipation). Treatment for JHS patients is hence necessary to 
reduce the gastrointestinal symptoms and a low FODMAP diet 
should be recommended. Future studies need to focus on the 
Figure 2. Margins plot for pain, bloating, diarrhea, constipation and average score.
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association of gastrointestinal symptoms in JHS patients in or-
der to approach more suitable treatment on IBS patients with 
JHS.
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